These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 34623894)
21. Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. Hall WA; Goodman KA Radiat Oncol; 2019 Jun; 14(1):114. PubMed ID: 31242912 [TBL] [Abstract][Full Text] [Related]
22. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy. Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234 [TBL] [Abstract][Full Text] [Related]
23. Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT. Gkika E; Adebahr S; Kirste S; Schimek-Jasch T; Wiehle R; Claus R; Wittel U; Nestle U; Baltas D; Grosu AL; Brunner TB Strahlenther Onkol; 2017 Jun; 193(6):433-443. PubMed ID: 28138949 [TBL] [Abstract][Full Text] [Related]
24. Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma. Quan K; Sutera P; Xu K; Bernard ME; Burton SA; Wegner RE; Zeh H; Bahary N; Stoller R; Heron DE Pract Radiat Oncol; 2018; 8(2):95-106. PubMed ID: 29291966 [TBL] [Abstract][Full Text] [Related]
25. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. de Geus SWL; Eskander MF; Kasumova GG; Ng SC; Kent TS; Mancias JD; Callery MP; Mahadevan A; Tseng JF Cancer; 2017 Nov; 123(21):4158-4167. PubMed ID: 28708929 [TBL] [Abstract][Full Text] [Related]
26. Radiotherapy in the adjuvant management of pancreatic adenocarcinoma: is it helpful? Abrams RA Expert Rev Gastroenterol Hepatol; 2012 Apr; 6(2):149-61. PubMed ID: 22375521 [TBL] [Abstract][Full Text] [Related]
27. Daily dose to organs at risk predicts acute toxicity in pancreatic stereotactic radiotherapy. Loi M; Magallon-Baro A; Suker M; Van Eijck C; Hoogeman M; Nuyttens JJ Acta Oncol; 2020 Aug; 59(8):944-948. PubMed ID: 32207351 [No Abstract] [Full Text] [Related]
28. Role of radiation therapy in the management of locally advanced pancreatic cancer. Aref A; Berri R J Clin Oncol; 2012 May; 30(13):1564-5; author reply 1566-7. PubMed ID: 22412127 [No Abstract] [Full Text] [Related]
29. Dose Escalation in Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Meta-Analysis. Zaorsky NG; Lehrer EJ; Handorf E; Meyer JE Am J Clin Oncol; 2019 Jan; 42(1):46-55. PubMed ID: 29965809 [TBL] [Abstract][Full Text] [Related]
30. Is there a role for intraoperative radiation therapy in patients with resected pancreatic adenocarcinoma? Meyer JJ; Crane CH Ann Surg Oncol; 2009 Aug; 16(8):2081-3. PubMed ID: 19526207 [No Abstract] [Full Text] [Related]
31. Radiation therapy for unresectable pancreatic adenocarcinoma: population-based trends in utilization and survival rates in the United States. Shapiro M; Rashid NU; Huang Q; Galper SL; Boosalis VA; Whang EE; Gold JS JAMA Surg; 2015 Mar; 150(3):274-7. PubMed ID: 25629219 [No Abstract] [Full Text] [Related]
33. Neoadjuvant treatment of pancreatic adenocarcinoma: Chemoradiation or stereotactic body radiation therapy? Huguet F; Cerbai C; Ta MH; Sarrade T; Evin C; Aziez S; Rivin Del Campo E; Durand B; Loi M Cancer Radiother; 2022 Oct; 26(6-7):858-864. PubMed ID: 35987811 [TBL] [Abstract][Full Text] [Related]
34. [Stereotactic body radiotherapy for locally advanced pancreatic cancer: A systemic review]. Tonneau M; Lacornerie T; Mirabel X; Pasquier D Cancer Radiother; 2021 May; 25(3):283-295. PubMed ID: 33423968 [TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival. Allendorf JD; Lauerman M; Bill A; DiGiorgi M; Goetz N; Vakiani E; Remotti H; Schrope B; Sherman W; Hall M; Fine RL; Chabot JA J Gastrointest Surg; 2008 Jan; 12(1):91-100. PubMed ID: 17786524 [TBL] [Abstract][Full Text] [Related]
36. Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study. Comito T; Cozzi L; Zerbi A; Franzese C; Clerici E; Tozzi A; Iftode C; Navarria P; D'Agostino G; Fogliata A; Mancosu P; Tomatis S; Carnaghi C; Personeni N; Santoro A; Scorsetti M Eur J Surg Oncol; 2017 Apr; 43(4):735-742. PubMed ID: 28131670 [TBL] [Abstract][Full Text] [Related]
37. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469 [TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Jessup JM; Steele G; Mayer RJ; Posner M; Busse P; Cady B; Stone M; Jenkins R; Osteen R Arch Surg; 1993 May; 128(5):559-64. PubMed ID: 8098206 [TBL] [Abstract][Full Text] [Related]